Internal Medicine · Allen, TX
NPI
1336379783
Since 2009
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1105 Central Expy N Ste 235
Allen, TX, 75013
Phone (972) 747-6042
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.2M
170,397 services
Medicare patients, 2024
1,069
Average age 74
Drug cost, 2024
$6.0M
2,398 prescriptions
Company payments, 2025
$728
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark B Jennings was code J1439 (injection, ferric carboxymaltose, 1 mg), 14,250 times for 17 patients. In total Mark B Jennings billed 170,397 services in 212 codes, and Medicare paid $3.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-09-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 14,250 | 17 | $0.88 | $13K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 13,927 | 138 | $0.10 | $1,356 |
| J9299 Injection, nivolumab, 1 mg | Office | 12,780 | 25 | $24.63 | $315K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 11,600 | 31 | $44.83 | $520K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 8,700 | 67 | $4.40 | $38K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 8,000 | 17 | $0.06 | $456 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 7,380 | 22 | $39.17 | $289K |
| J9267 Injection, paclitaxel, 1 mg | Office | 6,968 | 28 | $0.08 | $559 |
| J0185 Injection, aprepitant, 1 mg | Office | 4,810 | 31 | $1.34 | $6,439 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 3,300 | 21 | $20.35 | $67K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,300 | 17 | $0.11 | $376 |
| Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Office | 3,260 | 28 | $45.83 | $149K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2,880 | 11 | $2.30 | $6,632 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,665 | 157 | $0.09 | $240 |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 1,410 | 14 | $36.24 | $51K |
By year: 2022 $3.4M for 195,507 services; 2023 $3.4M for 198,569 services; 2024 $3.2M for 170,397 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,159 | 275 | $7.56 | $8,767 |
| 80053 Clinical Chemistry | 1,055 | 258 | $10.28 | $11K |
| 83615 Clinical Chemistry | 767 | 142 | $5.88 | $4,511 |
| 36415 Venipuncture Blood Collection | 758 | 246 | $8.65 | $6,557 |
| 83735 Clinical Chemistry | 708 | 119 | $6.52 | $4,619 |
| 84100 Clinical Chemistry | 708 | 119 | $4.62 | $3,269 |
| 84550 Clinical Chemistry | 707 | 120 | $4.40 | $3,110 |
| 88185 Surgical Pathology Examination | 274 | 12 | $16.46 | $4,510 |
| 82728 Clinical Chemistry | 124 | 67 | $13.36 | $1,657 |
| 83550 Clinical Chemistry | 124 | 67 | $8.57 | $1,063 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark B Jennings prescribed most often to Medicare patients was Oxycodone Hcl, with 152 prescriptions and refills. In total Mark B Jennings wrote 2,398 Medicare prescriptions that cost $6.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Oxycodone Hcl Generic | 152 | 152 | 44 | $4,365 |
| Dexamethasone Generic | 116 | 126 | 39 | $1,729 |
| Anastrozole Generic | 114 | 205 | 25 | $2,071 |
| Prochlorperazine Maleate Generic | 106 | 106 | 62 | $1,660 |
| Potassium Chloride Generic | 101 | 121 | 27 | $1,691 |
| Hydroxyurea Generic | 97 | 188 | 21 | $2,040 |
| Ondansetron Hcl Generic | 85 | 85 | 48 | $857 |
| Prednisone Generic | 71 | 77 | 25 | $409 |
| Tamoxifen Citrate Generic | 70 | 179 | 18 | $2,576 |
| Acyclovir Generic | 70 | 87 | 12 | $589 |
| Gabapentin Generic | 58 | 60 | Under 11 | $506 |
| Eliquis Apixaban | 57 | 57 | Under 11 | $32K |
| Imbruvica Ibrutinib | 54 | 54 | Under 11 | $900K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 52 | 70 | 39 | $623 |
| Ondansetron Odt Ondansetron | 50 | 50 | 29 | $859 |
Brand drugs: 489 claims; generic drugs: 1,909 claims; opioid claims: 276.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark B Jennings $728 ($728 in general payments such as food, travel and fees) from 10 companies. The largest payer was Pfizer Inc. with $231.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 20 | $231 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $158 |
| Caris MPI, Inc. | 2 | $141 |
| BeOne Medicines USA, Inc. ONC | 2 | $52.15 |
| Abbvie Inc. ABBV | 2 | $43.49 |
| Astellas Pharma US Inc 4503.T | 2 | $31.22 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $22.42 |
| Array Biopharma Inc PFE | 1 | $18.3 |
| EMD Serono, Inc. MRK.DE | 1 | $15.62 |
| GlaxoSmithKline, LLC. GSK | 1 | $14.91 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.